"Markers "
"Biochemical hyperandrogenism is based on the measurement of free testosterone, free androgen index, or calculated bioavailable testosterone, androstenedione and dehydroepiandrosterone sulphate 20."
"T1: small uniform follicles are low in signal while the central stroma is of intermediate signal (vs normal myometrium)"
"T2: follicles have high T2 signal while the central stroma is of comparatively low T2 signal 8"
"The 2018 International Evidence-based Guideline criteria (based on the 2003 Rotterdam criteria, updated in 2023) 23 are used to make the diagnosis of PMOS after exclusion of other aetiologies (e.g. congenital adrenal hyperplasia, Cushing syndrome, and/or an androgen-secreting tumour) and require at least two of the following 4,18,23:"
Expected headings
"Markers "
"Associations"
"Polyendocrine metabolic ovarian syndrome (PMOS), also known as hyperandrogenic anovulation, and previously known as polycystic ovarian syndrome (PCOS), is a multisystem condition affecting endocrine, metabolic, reproductive, dermatological and psychological health. It is not associated with an increase in the number of abnormal ovarian cysts 26."
"Polyendocrine metabolic ovarian syndrome (PMOS), also known as hyperandrogenic anovulation, and previously known as polycystic ovarian syndrome (PCOS), is a multisystem condition affecting endocrine, metabolic, reproductive, dermatological and psychological health. It is not associated with an increase in the number of abnormal ovarian cysts 26."
"Biochemical hyperandrogenism is based on the measurement of free testosterone, free androgen index, or calculated bioavailable testosterone, androstenedione and dehydroepiandrosterone sulphate 20."
"ovarian volume ≥10 mL, ensuring no corpora lutea, cysts or dominant follicles are present"
"postmenopausal women presenting with new-onset, severe or worsening hyperandrogenism including hirsutism, require further investigation to rule out androgen-secreting tumours and ovarian hyperthecosis"